On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the November 2024 CRG meeting. Actions in this consultation include:
- Apomorphine (APO-go Pod) – amber
- Aflibercept 8mg – red, second line
- Kay-Cee-L – discontinued, remove from formulary
- Varenicline – green, first choice alongside cytisine and NRT
- NovoRapid FlexTouch – discontinued, remove from formulary
- Latanoprost / netarsudil – green (specialist advice)
- Danicopan – red
- Belzutifan – red
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
This consultation will run for six weeks and closes at 5pm on Monday 30th December 2024. To take part, visit the consultations page.